Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009 | Hematology Meeting Reports (formerly Haematologica Reports)

Current Issue

Vol. 3 No. 3

12 June 2009

View this Issue

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009

Published: 12 June 2009

Proceedings

7th Meeting New Insight in Hematology

Teodoro Chisesi

https://doi.org/10.4081/hmr.v3i3.590

230

PDF: 307
- PDF

Articles

Molecular targeted therapies for indolent lymphomas: where are we?

G Saglio, G Parvis, M Bosa

https://doi.org/10.4081/hmr.v3i3.554

211

PDF: 214
- PDF
The indolent extranodal lymphomas: What is the role of radiation therapy?

RT Hoppe

https://doi.org/10.4081/hmr.v3i3.555

207

PDF: 718
- PDF
Alterations of microenvironment in multiple myeloma patients: interactions between myeloma cells and osteoprogenitor cells

N Giuliani, V Rizzoli

https://doi.org/10.4081/hmr.v3i3.556

210

PDF: 263
- PDF
New treatment options for elderly myeloma patients: the Italian experience

A Palumbo, M Genuardi, S Bringhen

https://doi.org/10.4081/hmr.v3i3.557

220

PDF: 278
- PDF
The road to cure in multiple myeloma: incorporation of novel agents into autologous stem cell transplantation

M Cavo, E Zamagni, P Tacchetti, A Brioli, C Pallotti, L Pantani, M Ceccolini, A Petrucci, N Testoni, C Terragna, G Marzocchi, S Durante, P Tosi, M Baccarani

https://doi.org/10.4081/hmr.v3i3.558

213

PDF: 131
- PDF
The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma

A Maiolino, V Tietsche de Moraes Hungria, M Nucci, C De Souza

https://doi.org/10.4081/hmr.v3i3.559

199

PDF: 204
- PDF
The role of maintenance treatment in myeloma

M Attal

https://doi.org/10.4081/hmr.v3i3.560

174

PDF: 195
- PDF
Have maintenance rituximab and RIC allograft blown away the need for autografts in follicular lymphoma?

AH Goldstone

https://doi.org/10.4081/hmr.v3i3.561

198

PDF: 131
- PDF
Reduced-intensity conditioning for allograft after cytoreductive autograft in relapsed/ resistant Hodgkin’s lymphoma

AM Carella, E Todisco, A Congiu, L Castagna, G Pica, G Beltrami, S Nati, R Vimercati, E Rossi, M Spriano, G Catania, A Santoro

https://doi.org/10.4081/hmr.v3i3.563

241

PDF: 144
- PDF
Long-term results of reduced-intensity conditioning followed by allogeneic transplantation in relapsed lymphomas

P Corradini, A Dodero, L Farina, R Fanin, F Patriarca, R Miceli, P Matteucci, R Scimè, F Narni, S Dalto, C Carniti, A Bacigalupo, F Bonifazi, A Olivieri, C Tarella

https://doi.org/10.4081/hmr.v3i3.564

307

PDF: 184
- PDF
Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

BKL Duarte, AC Vigorito, FJP Aranha, R Baldissera, ECM Miranda, IL Lorand-Metze, KB Pagnano, CA De Souza

https://doi.org/10.4081/hmr.v3i3.566

218

PDF: 153
- PDF
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification?

PP Piccaluga, F Bacci, E Sabattini, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Bertuzzi, C Agostinelli, MT Sista, C Laterza, S Parisi, SA Pileri

https://doi.org/10.4081/hmr.v3i3.567

231

PDF: 349
- PDF
High-dose CHOP in the rituximab era: still a place?

B Coiffier

https://doi.org/10.4081/hmr.v3i3.568

220

PDF: 243
- PDF
Radiotherapy in the rituximab era: still a place?

M Pfreundschuh

https://doi.org/10.4081/hmr.v3i3.569

267

PDF: 145
- PDF
S.J. Horning Biomarkers in diffuse large B-cell lymphoma

SJ Horning

https://doi.org/10.4081/hmr.v3i3.570

195

PDF: 368
- PDF
High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?

U Vitolo, A Chiappella, B Botto

https://doi.org/10.4081/hmr.v3i3.571

184

PDF: 247
- PDF
Recent advances in the pathology of idiopathic thrombocytopenic purpura

L Catani

https://doi.org/10.4081/hmr.v3i3.572

231

PDF: 787
- PDF
Idiopathic thrombocytopenic purpura in adults: the treatment paradigm

F Zaja, R Fanin

https://doi.org/10.4081/hmr.v3i3.573

188

PDF: 564
- PDF
Thrombopoietin receptor agonists in the treatment of chronic immune thrombocytopenic purpura

A Cuker, EY Chiang, DB Cines

https://doi.org/10.4081/hmr.v3i3.574

274

PDF: 902
- PDF
Are we getting closer to understanding the pathogenesis of chronic lymphocytic leukemia?

F Caligaris-Cappio, C Scielzo, S Bertilaccio, M Muzio, P Ghia

https://doi.org/10.4081/hmr.v3i3.575

266

PDF: 393
- PDF
The continuing search for the cell of origin of chronic lymphocytic leukemia

M Ferrarini

https://doi.org/10.4081/hmr.v3i3.576

182

PDF: 631
- PDF
Molecular cytogenetic lesions in chronic lymphocytic leukemia

A Cuneo, F Cavazzini, M Ciccone, M Dabusti, F Cibien, G Daghia, O Sofritti, GM Viglione, GM Rigolin

https://doi.org/10.4081/hmr.v3i3.577

216

PDF: 830
- PDF
What is gene profiling contributing to the characterization of chronic lymphocytic leukemia

R Foà, A Guarini, I Del Giudice, S Tavolaro, S Chiaretti

https://doi.org/10.4081/hmr.v3i3.578

168

PDF: 143
- PDF
The impact of diagnosis on the therapeutic management of chronic lymphocytic leukemia

V Liso, R Rizzi

https://doi.org/10.4081/hmr.v3i3.579

212

PDF: 235
- PDF
How close are we to curing chronic lymphocytic leukemia?

MJ Keating

https://doi.org/10.4081/hmr.v3i3.580

179

PDF: 231
- PDF
Cyclophosphamide in chronic lymphocytic leukemia first line: final results of Chronic Lymphocytic Leukemia 8 Study

M Gobbi

https://doi.org/10.4081/hmr.v3i3.581

5599

PDF: 738
- PDF
Lenalidomide: an emerging option in chronic lymphocytic leukemia

A Ferrajoli, SM O’Brien, SM O’Brien, S Faderl1, S Faderl1, WG Wierda, WG Wierda, JM Reuben, JM Reuben, MJ Keating, MJ Keating

https://doi.org/10.4081/hmr.v3i3.582

196

PDF: 204
- PDF
Ofatumumab: a second generation anti-CD20 monoclonal antibody in chronic lymphocytic leukemia

M Montillo

https://doi.org/10.4081/hmr.v3i3.583

184

PDF: 351
- PDF
Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors

G Finazzi, T Barbui

https://doi.org/10.4081/hmr.v3i3.584

254

PDF: 535
- PDF
New biologic and therapeutic insights in Hodgkin’s lymphoma

GP Canellos, W Rosenberg

https://doi.org/10.4081/hmr.v3i3.585

202

PDF: 222
- PDF
Treatment approaches in early stage Hodgkin’s lymphoma

DJ Straus

https://doi.org/10.4081/hmr.v3i3.586

195

PDF: 484
- PDF
Advanced Hodgkin’s lymphoma: doxorubicin, bleomycin, vinblastine, dacarbazine and beyond

V Diehl

https://doi.org/10.4081/hmr.v3i3.587

252

PDF: 268
- PDF
Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone outside German Hodgkin Study Group: the Italian experience

S Luminari, M Federico, A Montanini, E Iannitto, G Polimeno, PG Gobbi

https://doi.org/10.4081/hmr.v3i3.588

219

PDF: 498
- PDF
Treatment of refractory Hodgkin’s lymphoma: a puzzle to merge

A Santoro, A Anastasia, R Mazza

https://doi.org/10.4081/hmr.v3i3.589

157

PDF: 278
- PDF
Blastic plasmacytoid dendritic cell neoplasm

F Facchetti, M Ungari, D Marocolo, S Lonardi, W Vermi

https://doi.org/10.4081/hmr.v3i3.553

4823

PDF: 4170
- PDF

© PAGEPress 2008-2025 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy